Bibliography
- Drugs intended to treat life-threatening and severely-debilitating illnesses, 21 Code of Federal Regulations (C.F.R.) Subpart E Sect. 312.80-312.84
- The Food and Drug Administration Modernization Act (FDAMA) of 1997. Public Law. 1997;105-15
- Accelerated approval of new drugs for serious or life-threatening illnesses, 21 C.F.R. Subpart H Sect. 314.500-314.560 and 21 C.F.R. Subpart E Sect. 601.40-601.46
- The Prescription Drug User Fee Act (PDUFA) of 1992, Public Law 1992;102-571
- The Food and Drug Administration Safety and Innovation Act (FDASIA). Public Law. 2012;112-44
- Cassino C, Orfali M, Charnigo RJ, Marsden DL. Rare and orphan diseases challenges: clinical development and clinical practice. J Rare Disorders 2013;1:1-3
- Independent evaluation of FDA's first cycle review performance—retrospective analysis final report text. Booz Allen Hamilton, Inc., FDA, Washington, DC. 2006. Available from: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119469.htm [Last accessed 11 April 2013]
- FDAVoice, Early communication: A key to reduced drug development and approval times. Pariser A. FDA/CDER, Washington, DC; 2013. Available from: http://blogs.fda.gov/fdavoice/index.php/2013/02/early-communication-a-key-to-reduced-drug-development-and-approval-times/ [Last accessed 11 April 2013]
- Pariser AR, Slack DJ, Bauer LJ, et al. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010. Drug Discov Today 2012;17:898-904
- About FDA, FY 2012 innovative drug approvals. FDA, Washington, DC; 2012. Available from: http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm276385.htm [Last accessed 11 April 2013]
- CDER new drug review: 2012 update. Jenkins JK. FDA, Washington, DC; 2012. Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM331454.pdf [Last accessed 11 April 2013]
- Downing NS, Aminawung JA, Shah ND, et al. Regulatory review of novel therapeutics—comparison of three regulatory agencies. N Engl J Med 2012;366:2284-93
- Regulatory information, Frequently asked questions: breakthrough therapies. FDA, Washington, DC; 2012. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm341027.htm [Last accessed 11 April 2013]
- Sasinowski FJ. Quantum of effectiveness evidence in FDA's approval of orphan drugs: cataloguing FDA's flexibility in regulating therapies for persons with rare disorders. Drug Inf J 2012;46:238-63